Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle

被引：38
|
作者：
Patel, Harun M. [1 ]
Pawara, Rahul [1 ]
Ansari, Azim [1 ]
Noolvi, Malleshappa [2 ]
Surana, Sanjay [1 ]
机构：
[1] RC Patel Inst Pharmaceut Educ & Res, Dept Pharmaceut Chem, Shirpur 425405, Maharashtra, India
[2] Shree Dhanvantary Pharm Coll, Dept Pharmaceut Chem, Surat 3941110, Gujarat, India
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2017年 / 25卷 / 10期
关键词：
Quinazoline; Non Small Cell Lung Cancer; T790M EGFR; CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; PAN-ERBB INHIBITOR; PHASE-II TRIAL; ACQUIRED-RESISTANCE; T790M MUTATION; IRREVERSIBLE INHIBITORS; ACCURATE DOCKING; GEFITINIB;
D O I：
10.1016/j.bmc.2017.03.039
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The epidermal growth factor receptor (EGFR) T790M mutant is found in about 50% of clinically acquired resistance to gefitinib among patients with non-small cell lung cancer (NSCLC). New derivatives of 4(3H)-quinazolinones were synthesized and evaluated for their inhibitory activity against NSCLC. The results of the study demonstrated that compound 79, 7-chloro-3-(5-(4-methoxypheny1)-1,3,4-thiadiazol-2-y1)-2-phenylquinazolin-4(3H)-one was found to be the most potent compounds of the series with IC50 value of 0.031 mu M against mutant T790M/L858R EGFR. Compounds 15, 51, 73, 75, 78, 79 and 96 were less potent against A549 (WT EGFR and k-Ras mutation) and HT-29 (non-special gene type) cells, showing a high safety index. The obtained results showed that compounds 15, 51, 73, 75, 78, 79 and 96 could be the promising template to overcome drug resistance mediated by the EGFR T790 Mutant. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2713 / 2723
页数：11
相关论文
共 50 条
  • [31] Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
    Juchum, Michael
    Guenther, Marcel
    Laufer, Stefan A.
    DRUG RESISTANCE UPDATES, 2015, 20 : 12 - 28
  • [32] Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors
    Hu, Xiuqin
    Wang, Disha
    Tong, Yi
    Tong, Linjiang
    Wang, Xia
    Zhu, Lili
    Xie, Hua
    Li, Shiliang
    Yang, You
    Xu, Yufang
    FRONTIERS IN CHEMISTRY, 2017, 5
  • [33] Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance
    Temraz, Sally
    Mukherji, Deborah
    Shamseddine, Ali
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 101 : 151 - 157
  • [34] Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal
    Togashi, Yosuke
    Hayashi, Hidetoshi
    Okamoto, Kunio
    Fumita, Soichi
    Terashima, Masato
    de Velasco, Marco A.
    Sakai, Kazuko
    Fujita, Yoshihiko
    Tomida, Shuta
    Nakagawa, Kazuhiko
    Nishio, Kazuto
    LUNG CANCER, 2015, 88 (01) : 16 - 23
  • [35] Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
    Ercan, D.
    Zejnullahu, K.
    Yonesaka, K.
    Xiao, Y.
    Capelletti, M.
    Rogers, A.
    Lifshits, E.
    Brown, A.
    Lee, C.
    Christensen, J. G.
    Kwiatkowski, D. J.
    Engelman, J. A.
    Jaenne, P. A.
    ONCOGENE, 2010, 29 (16) : 2346 - 2356
  • [36] Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation
    Yao, Han
    Ren, Yuanyuan
    Wu, Feng
    Liu, Jiadai
    Li, Jianheng
    Cao, Longcai
    Yan, Ming
    Li, Xingshu
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 275
  • [37] Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
    Murtuza, Ayesha
    Bulbul, Ajaz
    Shen, John Paul
    Keshavarzian, Parissa
    Woodward, Brian D.
    Lopez-Diaz, Fernando J.
    Lippman, Scott M.
    Husain, Hatim
    CANCER RESEARCH, 2019, 79 (04) : 689 - 698
  • [38] Emerging combination therapies to overcome resistance in EGFR-driven tumors
    Ratti, Margherita
    Tomasello, Gianluca
    ANTI-CANCER DRUGS, 2014, 25 (02) : 127 - 139
  • [39] Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
    Cooper, Alissa J.
    Sequist, Lecia, V
    Lin, Jessica J.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (08) : 499 - 514
  • [40] Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR
    Wu, Jianwei
    Chen, Wenteng
    Xia, Guangxin
    Zhang, Jing
    Shao, Jiaan
    Tan, Biqin
    Zhang, Chunchun
    Yu, Wanwan
    Weng, Qinjie
    Liu, Haiyan
    Hu, Miao
    Deng, Hailin
    Hao, Yu
    Shen, Jingkang
    Yu, Yongping
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (10): : 974 - 978
12345